INTRODUCTION {#s1}
============

Colorectal cancer (CRC) caused almost 700,000 deaths worldwidely every year, making it the world\'s fourth most deadly cancer \[[@R1]\]. It was the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012 \[[@R2]\]. The lifestyle changes in past low-CRC-risk countries resulted in rapid growth of colorectal cancer and the 5-year survival rate was still poor despite the progress of the treatment \[[@R3]--[@R6]\]. Pretreatment predicting indexes are in dire need to forecast potential of the tumor recurrence and prognosis for that the majority of the available prognostic markers are assessed postoperatively. The clinical and pathological TNM stages, the number of resected lymph nodes (nLNs), carcino-embryonic antigen (CEA), the lymphovascular invasion (LVI), the perineural invasion, in addition to some molecular markers (eg. PinX1, RAS, BRAF, MMR and so on) have all been identified as prognostic factors \[[@R7]--[@R11]\], however several weaknesses limited their application in routine clinical practice, such as high costs, lack of standardization, low consistency, and poor reproducibility \[[@R7], [@R12], [@R13], [@R14]\]. Therefore, finding a proper prognostic factors to assist coloractal cancer patients in guiding appropriate treatment to improve the therapeutic effectiveness is extremely urgent.

Prior studies showed that systemic inflammatory response (SIR) status played a vital role in tumor progression and therapeutic response \[[@R15]--[@R19]\]. The levels of platelets and lymphocytes represents the systemic inflammatory response (SIR), and they are easily obtained by widely used peripheral blood test. Platelet-lymphocyte ratio (PLR) as a combination of these two factors has been reported to be associated with poor prognosis in different tumor types, including CRC \[[@R20]--[@R32]\], but some other studies drew a different conclusion \[[@R33]--[@R43]\]. In brief, independent research results of the relationship between PLR and its impact on survival and clinical features were still inconsistent, partly due to limited published studies previously, various confounding factors and less detailed analysis. Recently, a lot of new studies on this issue were published continuously. Thus the aim of our study was to perform a systemic review and meta-analysis with all eligible current evidence to clarify this relationship and to evaluate whether PLR was an independent risk factors for the prognosis of patients with colorectal cancer.

RESULTS {#s2}
=======

Literature search and study selection {#s2_1}
-------------------------------------

A total of 194 relevant publications were initially retrieved. Of these, 29 duplicates were removed, 134 publications were excluded because the studies were animal experiment, literature reviews, comments, letters, or unrelated studies based on the titles and abstracts screening. After reading the full text, 7 publications were excluded due to irrelevant publications, studies with overlapping case series or lack of sufficient data for analysis, Therefore, a total of 24 publications with 13719 patients were included \[[@R20]--[@R43]\]. All of these studies contained the required information and evaluated the correlation between PLR and the prognosis of CRC. Figure [1](#F1){ref-type="fig"} presents a summary of the study selection process.

![Flow chat of literature search and study selection](oncotarget-08-32356-g001){#F1}

Study characteristics {#s2_2}
---------------------

The main features of the 24 selected studies are shown in Table [1](#T1){ref-type="table"}. From the 24 studies, fourteen publications were originated from the Asian (eight from China, three from Korea, three from Japan), nine were performed in Caucasian population (four from the UK, one from Hungary, one from Canada, one from Australia, one from Austria, one from Italy), and one from USA with mixed races. The OS was investigated in 22 studies, the DFS rate was analyzed in 12 studies, the CSS rate was evaluated in 4 studies, and the RFS rate was reported in 2 studies. These eligible studies were published from 2012 to 2016. Thirteen of these directly provided HR in multivariate analysis, and survival data of nine studies were extracted from univariate analysis while survival data of two studies were extracted from survival curves. The extracted data in detail were presented in [Supplementary Table S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}, while detailed NOS scores of each included study were presented in [Supplementary Table S4](#SD1){ref-type="supplementary-material"}.

###### Study characteristics

  Author       Year   Country     Ethnicity   Location            Na     Sex(male/female)   Stage         Metastasis   Treatmentb    Survival analysis   Analysis   NOS score
  ------------ ------ ----------- ----------- ------------------- ------ ------------------ ------------- ------------ ------------- ------------------- ---------- -----------
  Azab         2014   USA         Mixed       Colorectal cancer   580    273/307            I/II/III/IV   Y            Surgery       OS/DFS              M/M        8
  Baranyai     2014   Hungary     Caucasian   Colorectal cancer   336    180/156            I/II/III/IV   N            Surgery       OS/DFS              U/U        5
  Baranyai     2014   Hungary     Caucasian   Colorectal cancer   118    80/38              IV            Y            Surgery       OS                  U          5
  Carruthers   2012   UK          Caucasian   Rectal cancer       115    75/40              I/II/III      Y            Surgery       OS/DFS              U/U        6
  Chan         2016   Australia   Caucasian   Colorectal cancer   1623   801/882            I/II/III      N            Surgery       OS                  U          8
  Choi         2015   Canada      Caucasian   Colorectal cancer   549    296/253            I/II/III      N            Surgery       OS/RFS              U/U        8
  He           2013   China       Asian       Colorectal cancer   243    155/88             IV            Y            Non surgery   OS                  M          8
  Kwon         2012   Korea       Asian       Colorectal cancer   200    123/77             I/II/III/IV   Y            Surgery       OS                  M          8
  Li           2016   China       Asian       Rectal cancer       140    81/59              I/II/III      N            Surgery       OS/DFS              U/U        7
  Li           2016   China       Asian       Colorectal cancer   5336   3167/2169          I/II/III      Y            Surgery       OS/DFS              M/M        6
  Li           2015   China       Asian       Colon cancer        110    58/52              IV            Y            Surgery       OS                  M          7
  Mori         2015   Japan       Asian       Colorectal cancer   157    87/65              I/II/III      N            Surgery       DFS                 U          6
  Neal         2015   UK          Caucasian   Colorectal cancer   302    192/110            IV            Y            Surgery       OS/CSS              U/U        7
  Neofytou     2014   UK          Caucasian   Colorectal cancer   140    88/52              IV            Y            Surgery       OS/DFS              M/M        9
  Neofytou     2015   UK          Caucasian   Colorectal cancer   140    88/52              IV            Y            Surgery       CSS                 U          9
  Ozawa        2015   Japan       Asian       Colorectal cancer   234    142/92             II            N            Surgery       DFS/CSS             M/M        7
  Passardi     2016   Italy       Caucasian   Colorectal cancer   289    174/115            I/II/III/IV   Y            Non surgery   OS                  M/         7
  Son          2013   Korea       Asian       Colon cancer        624    368/256            I/II/III      N            Surgery       OS/DFS              M/M        7
  Song         2015   Korea       Asian       Colorectal cancer   177    83/94              IV            N            Non surgery   OS                  U          5
  Sun          2014   China       Asian       Colon cancer        255    135/120            I/II/III      N            Surgery       OS/DFS              M/M        7
  Szkandera    2014   Austria     Caucasian   Colon cancer        372    217/155            II/III        N            Surgery       OS                  M          7
  Toiyama      2013   Japan       Asian       Rectal cancer       84     62/22              I/II/III      N            Surgery       OS/DFS              U/U        6
  Ying         2014   China       Asian       Colorectal cancer   205    144/61             I/II/III      N            Surgery       OS/CSS/RFS          M/M/M      7
  You          2016   China       Asian       Colorectal cancer   1314   785/529            I/II/III/IV   Y            Surgery       OS                  M          6
  Zou          2016   China       Asian       Colorectal cancer   216    137/79             I/II/III/IV   Y            Surgery       OS/DFS              M/M        7

^a^ Number of included patients.

^b^Unsurgery includes patients undergoing chemotherapy, chemoradiotherapy, or other treatment, but not doing surgery. Surgery including patients getting surgery with or without other treatment.

Abbreviations: NA: not available; OS: overall survival; DFS: disease-free survival; CRM: cancer-ralated mortality; TLR: Time to local recurrence; RFS: recurrence-free survival; CSS: Cancer-specific survival; M: multivariate analysis; U: univariate analysis; NOS: Newcastle-Ottawa Quality Assessment Scale; PLR: platelet-lymphocyte ratio.

Prognostic value of PLR for CRC patients {#s2_3}
----------------------------------------

Twenty-two studies containing 13328 CRC patients reported the impact of PLR on OS, which showed the existence of heterogeneity across the studies (I^2^ = 58.6%, Ph \< 0.001). We detected that higher PLR predicate shorter OS for CRC patients (HR = 1.47; 95%CI, 1.28-1.68; *p* \< 0.001)(Table [2](#T2){ref-type="table"}, Figure [2a](#F2){ref-type="fig"}). Furthermore, twelve studies containing 8217 CRC patients suggested that elevated PLR was significantly associated with a poor DFS (HR = 1.51; 95% CI, 1.20-1.91; *p* = 0.001) (Figure [2b](#F2){ref-type="fig"}). Increased PLR predicated a worse RFS (HR = 1.39; 95% CI, 1.03-1.86; *p* = 0.001) in the combination of 2 studies containing 754 CRC patients, however it was not related to CSS (HR = 1.14; 95% CI, 0.92-1.42; *p* = 0.223) (Table [2](#T2){ref-type="table"}) in the combination of four studies containing 881 CRC patients.

![Results of prognostic analysis for PLR in CRC for OS **a**. and DFS **b**.](oncotarget-08-32356-g002){#F2}

###### The pooled data on survival of meta-analysis

  Variables                *N*^a^                         Case^b^                        Pooled data       Heterogeneity   *N*^a^    Case^b^   Pooled data   Heterogeneity                                           
  ------------------------ ------------------------------ ------------------------------ ----------------- --------------- --------- --------- ------------- --------------- ------------------- --------- --------- ---------
  Overall                  22                             13328                          1.47(1.28,1.68)   \<0.001         58.60%    \<0.001   12            8217            1.51(1.2,1.91)      0.001     68.10%    \<0.001
  **By ethnicity**                                                                                                                                                                                                   
  Caucasian                9                              3844                           1.6(1.3,1.96)     \<0.001         60.00%    0.01      3             591             1.9(1.06,3.4)       0.031     73.40%    0.023
  Asian                    12                             8904                           1.41(1.17,1.7)    0.001           57.00%    0.008     8             7046            1.37(1.06,1.78)     0.017     60.80%    0.013
  Mixed                    1                              580                            1.12(0.71,1.77)   0.629           /         /         1             580             1.35(0.9,2.03)      0.148     /         /
  **By analysis method**                                                                                                                                                                                             
  Univariate               10                             3687                           1.57(1.26,1.96)   \<0.001         70.70%    \<0.001   5             832             1.96(1.31,2.94)     0.011     50.90%    0.087
  Multivariate             12                             9641                           1.32(1.17,1.48)   \<0.001         41.00%    0.068     7             7385            1.27(1.02,1.6)      0.036     57.50%    0.028
  **By treatment**                                                                                                                                                                                                   
  Surgery                  19                             12619                          1.51(1.3,1.74)    \<0.001         55.1%     0.002     12            8217            1.51(1.2,1.91)      0.001     68.10%    \<0.001
  Non surgery              3                              709                            1.31(0.9,1.89)    0.157           71.2%     0.031                                                                           
  **By cut-off**                                                                                                                                                                                                     
  Single cut-off           15                             10257                          1.61(1.36,1.89)   \<0.001         47.90%    0.02      10            7382            1.69(1.28,2.22)     0.001     67.70%    0.001
  Multiple cut-offs        7                              3071                           1.27(1.03,1.56)   0.026           62.50%    0.014     2             835             1.04(0.65,1.67)     0.856     69.50%    0.07
  \<200                    7                              1043                           1.50(1.24,1.81)   \<0.001         3.40%     0.4       6             870             1.72(1.34,2.2)      \<0.001   \<0.01%   0.553
  ≥200                     15                             12245                          1.44(1.22,1.71)   \<0.001         68.10%    \<0.001   6             7347            1.36(0.99,1.87)     0.059     77.90%    \<0.001
  **By sample size**                                                                                                                                                                                                 
  \<200                    7                              884                            1.8(1.44,2.26)    \<0.001         \<0.01%   0.698     5             636             1.62(1.2516,2.11)   \<0.001   \<0.01%   0.653
  ≥200                     15                             12444                          1.39(1.19,1.63)   \<0.001         66.00%    \<0.001   7             7581            1.46(1.06,2.01)     0.019     78.10%    \<0.001
  **By study result**                                                                                                                                                                                                
  Positive                 11                             5007                           1.57(1.41,1.74)   \<0.001         12.80%    0.325     5             887             1.65(1.32,2.05)     \<0.001   2.50%     0.392
  Negative                 11                             8221                           1.29(1.05,1.59)   0.016           62.50%    0.002     7             7330            1.36(0.99,1.87)     0.058     73.20%    0.001
  **By metastatic**                                                                                                                                                                                                  
  Yes                      12                             8963                           1.34(1.16,1.54)   \<0.001         38.70%    0.083     5             6387            1.17(1.04,1.33)     0.012     13.80%    0.327
  No                       10                             4365                           1.62(1.27,2.06)   0.001           65.30%    0.002     7             1830            1.89(1.15,3.08)     0.011     77.00%    \<0.001
  **By location**                                                                                                                                                                                                    
  Colorectal cancer        15                             11628                          1.47(1.26,1.71)   \<0.001         64.40%    \<0.001   7             6999            1.71(1.23,2.37)     0.001     76.80%    \<0.001
  Rectal cancer            3                              339                            1.65(1.17,2.34)   0.005           \<0.01%   0.914     3             339             1.5(1.07,2.08)      0.017     \<0.01%   0.615
  Colon cancer             4                              1361                           1.49(0.92,2.4)    0.183           69.40%    0.02      2             879             0.89(0.65,1.21)     0.45      42.70%    0.186
  **By NOS**                                                                                                                                                                                                         
  \<6                      3                              631                            2.02(1.06,3.87)   0.034           74.00%    0.021     1             336             3.4(2.0,5.79)       \<0.001   /         /
  ≥6                       19                             12597                          1.34(1.24,1.45)   \<0.001         43.50%    0.023     11            7881            1.35(1.11,1.65)     0.002     50.90%    0.026
                           **Cancer-specific survival**   **Recurrence-free survival**                                                                                                                               
  Overall                  4                              881                            1.14(0.92,1.42)   0.223           63.70%    0.041     2             754             1.39(1.03,1.86)     0.03      13.50%    0.282

^a^ Numbers of studies included in the meta-analysis.

^b^ Number of patients of included studies.

Abbreviations: NA: not available; HR: hazard ratio; 95%CI: confidence interval; *P*: *p* value of pooled HR; *I*^2^: value of Higgins I-squared statistics; *Ph*: *p* value of Heterogeneity test.

To explain the source of heterogeneity, we further performed a subgroup analysis by ethnicity, analysis method, major treatment therapy, respective cut-off value, sample size, metastasis status, tumor location and NOS score. The higher PLR was, the shorter OS and DFS were showed both in Caucasian ( \[OS: HR = 1.6; 95% CI, 1.3-1.96; *p* \< 0.001\]; \[DFS: HR = 1.9; 95% CI, 1.06-3.4; *p* = 0.031\]) and Asian groups ( \[OS: HR = 1.41; 95% CI, 1.17-1.7; *p* = 0.001\]; \[DFS: HR = 1.37; 95% CI, 1.06-1.78; *p* = 0.017\]). Significant association were detected whether univariate analysis ( \[OS: HR = 1.57; 95% CI, 1.26-1.96; *p* \< 0.001\]; \[DFS: HR = 1.96; 95% CI, 1.31-2.94; *p* = 0.011\]) or multivariate ( \[OS: HR = 1.32; 95% CI, 1.17-1.48; *p* \< 0.001\]; \[DFS: HR = 1.27; 95% CI, 1.02-1.6; *p* = 0.036\]) analysis were used in original studies. Elevated PLR was strongly associated with poor OS in patients who underwent surgical resection ( \[OS: HR = 1.51; 95% CI, 1.3-1.74; *p* \< 0.001\]), but not in nonsurgery subgroup which involved limited studies ( \[OS: HR = 1.31; 95% CI, 0.9-1.89; *p* = 0.157\]) (Figure [3a](#F3){ref-type="fig"}). After enlarging the sample size by meta-analysis, we overthrow the old conclusion in the negative study result subgroup that PLR had nothing to do with OS. For metastatic colorectal cancer patients, increased PLR predicated a worse OS and DFS ( \[OS: HR = 1.34; 95% CI, 1.16-1.54; *p* \< 0.001\]; \[DFS: HR = 1.17; 95% CI, 1.04-1.33; *p* = 0.012\]), and this prognostic implication also existed in nonmetastatic CRC ( \[OS: HR = 1.62; 95% CI, 1.27-2.06; *p* = 0.001\]; \[DFS: HR = 1.89; 95% CI, 1.15-3.08; *p* = 0.011\]) (Figure [3b](#F3){ref-type="fig"}). Significant association were almost detected in all stratified analysis which further proved our results. More details about the subgroup analysis of OS and DFS were presented in Table [2](#T2){ref-type="table"}.

PLR and clinical characteristics of CRC patients {#s2_4}
------------------------------------------------

In addition, we examined the association between PLR and the clinical parameters of colorectal cancer (Table [3](#T3){ref-type="table"}). Peripheral higher PLR was detected to be associated with gender(OR = 0.8; 95% CI, 0.72-0.90; *p* \< 0.001), cancer location(OR = 1.54; 95% CI, 1.19-1.99; *p* = 0.001), poorer differentiation status (OR = 1.51; 95% CI, 1.26-1.81; *p* \< 0.001), higher tumor stage(OR = 1.25; 95% CI, 1.05-1.49; *p* = 0.012), higher T (OR = 2.13; 95% CI, 1.36-3.34; *p* = 0.001) stage and N stage(OR = 1.35; 95% CI, 1.17-1.54; *p* \< 0.001), more lymphovascular invasion (OR = 1.25; 95% CI, 1.09-1.43; *p* = 0.001), and recurrence(OR = 2.78; 95% CI, 1.36-5.68; *p* = 0.005) in colorectal cancer patients (Figure [4](#F4){ref-type="fig"}).

![Association between PLR and OS stratified by treatment **a**., metastatic **b**.](oncotarget-08-32356-g003){#F3}

![Association between PLR and tumor location **a**., differentiation **b**., stage **c**. and lymphovascular invasion **d**.](oncotarget-08-32356-g004){#F4}

###### The pooled data on clinical characteristics of included studies

  Variables                          *N*^a^   Case^b^   Pooled data       Heterogeneity             
  ---------------------------------- -------- --------- ----------------- --------------- --------- -------
  **Gender**                         13       9483                                                  
  Female                                      3908      Reference                                   
  Male                                        5575      0.8(0.72,0.90)    \<0.001         \<0.01%   0.512
  **Location**                       9        8262                                                  
  Rectaum                                     4261      Reference                                   
  Colon                                       4001      1.54(1.19,1.99)   0.001           51.80%    0.034
  **Differentiation**                8        7388                                                  
  Well and moderately                         6526      Reference                                   
  Poorly                                      862       1.51(1.26,1.81)   \<0.001         28.30%    0.202
  **Stage**                          7        3156                                                  
  I/II                                        1770      Reference                                   
  III/IV                                      1386      1.25(1.05,1.49)   0.012           46.00%    0.085
  **T**                              7        6419                                                  
  1,2                                         1516      Reference                                   
  3,4                                         4903      2.13(1.36,3.34)   0.001           51.10%    0.056
  **N**                              6        6583                                                  
  Negative(N0)                                3504      Reference                                   
  Positive(N1,2)                              3079      1.35(1.17,1.54)   \<0.001         22.80%    0.262
  **LVI(lymphovascular invasion)**   6        7951                                                  
  No                                          5733      Reference                                   
  Yes                                         2218      1.25(1.09,1.43)   0.001           \<0.01%   0.933
  **Recurrence**                     2        236                                                   
  Absent                                      192       Reference                                   
  Present                                     44        2.78(1.36,5.68)   0.005           \<0.01%   0.352
  **Chemotherapy**                   4        6670                                                  
  No                                          2214      Reference                                   
  Yes                                         4456      1.09(0.74,1.61)   0.674           72.00%    0.013

^a^ Numbers of studies included in the meta-analysis.

^b^ Number of patients of included studies.

Abbreviations: LVI: lymphovascular invasion; OR: odds ratio; 95%CI: confidence interval; *P*: *p* value of pooled HR; *I*2: value of *X*2 based I-squared statistics; *Ph*: *p* value of Heterogeneity test.

Sensitivity analysis and publication bias {#s2_5}
-----------------------------------------

To identify the source of heterogeneity across selected studies, sensitivity analysis was conducted by removing each study in turn from the analysis. The pooled ORs and HRs were not significantly changed, indicating the stability of our analyses. The funnel plots were largely symmetrical for OS in patients with CRC, and the results of the Begg\'s and Egger\'s tests showed no evidence of significant publication bias among the included studies (OS: Begg\'s test Pr \> \|z\| = 0.159, Egger\'s test *P* \> \|t\| = 0.130) (Figure [5a](#F5){ref-type="fig"}). But slight publication bias was seen in DFS (DFS: Begg\'s test Pr \> \|z\| = 0.064, Egger\'s test *P* \> \|t\| = 0.013). So a trim and fill method was used to estimate the asymmetry in the funnel plot (HR = 1.143; 95%CI, 0.903-1.447, *p* = 0.267)(Figure [5b](#F5){ref-type="fig"}).

![Egger\'s test for accessing publication biases for role of PLR on OS **a**. and DFS (**b**., after trim and fill method).](oncotarget-08-32356-g005){#F5}

DISCUSSION {#s3}
==========

This systematic review and meta-analysis, including 24 individual studies of 13719 patients, found that increased PLR was strongly associated with poor overall survival and recurrence-free survival in patient with colorectal cancer. However, PLR was unrelated to cancer-specific survival and disease-free survival after trim and fill method. The stratified analyses showed that elevated PLR was associated with poor outcome in both Caucasian and Asian population, univariate and multivariate analysis, metastatic and nonmetastatic CRC, and resected patients. However, we did not observe the significant association in nonsurgery subgroup for that the number of the included original studies in this subgroup is limited. For the negative study result subgroup, the HR of OS was 1.29 (95% CI, 1.05-1.59; *p* = 0.016), which meaned that after enlarging the sample size by meta-analysis, we overthrow the old conclusion that PLR had nothing to do with OS. Our finding confirmed the hypothesis that PLR was an appropriate prognostic factor for CRC patient survival.

Cancer progression and prognosis was determined not only by tumor characteristics but also by the host inflammatory response \[[@R44], [@R45]\]. Using clinical, inflammatory, and molecular biomarkers as CRC prognostic factors are increasingly interesting, but there remained a lack of reliable, reproducible, and low-cost markers that can be readily incorporated into routine practice to optimally predict prognosis and guide treatment \[[@R31]\]. Some combinations of the inflammatory response parameters (eg. lymphocytes, neutrophils, platelets and acute-phase proteins, which are simple and easy to measure using standardized and widely used assays) including platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and albumin/globulin ratio (AGR), have been performed to evaluate the prognosis in various cancers, including CRC, and so on \[[@R27], [@R33], [@R46]--[@R48]\]. There were many reasons for PLR\'s ideal prognostic role in CRC patient. Firstly, platelets secrete several tumor growth and angiogenic factors, which might influence tumor progression \[[@R49]\]. Secondly, while in antitumor reaction of the immune system, the CD8+ and CD4+ T-lymphocyte interaction among each other can induce tumor cell apoptosis, which can improve the survival of CRC patients for the chemotherapy efficacy \[[@R50]\]. These supported our finding that the PLR was a promising prognostic factors for the survival of CRC patients, which was consistent with previous meta-analysis \[[@R51]--[@R54]\], however, our study was to some extent superior to the previous studies because of much more included studied and patients, more detailed analyses and less limitation. We included all current eligible relative studies by systemic review and meta-analysis. We did subgroup analyses to explore the heterogeneity sources, besides we explored the relationship between PLR and the inferior clinical features.

By analyzing clinical factors, we found the relationship between the increased PLR and the clinical characteristics of CRC patients. PLR tended to be higher in colon cancer than rectum which need further explanation. Poorly differentiated cancer always accompanied with elevated PLR, for that poorly differentiated tumour cells growing faster with angiogenic and tumour growth factors secreted by platelet cell, such as platelet factor 4 (PF4), thrombospondin, vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-β) and platelet-derived growth factor (PDGF) \[[@R36]\]. Moreover, platelets reflected the invasive potential of CRC and was closely associated with lymphovascular invasion (LVI) \[[@R55]\]. PLR was a good prognostic marker in mCRC patients, because several studies have shown that platelets induce circulating tumor cell epithelial-mesenchymal transition and promote extravasation to metastatic sites \[[@R43], [@R56], [@R57]\]. Lymphocytes were involved in cancer immune surveillance which influenced the tumor recurrence to some extent \[[@R58]\]. Our study results indicated that the relationship between PLR and some clinical factors presented a new researching direction for future research. Moreover, the easily got PLR can be used to reflect some clinical characteristics which were difficult to obtain like tumour differentiation, lymphovascular invasion (LVI), recurrence and so on. Pretreatment blood test for PLR played a vital role in assessment of cancer characteristics and patients prognosis.

There were limitations in our systematic review. First, the included studies were almost retrospective studies and more studies with prospective design were warranted in future. Second, eleven enrolled studies applied univariate analysis only (without providing multivariate analysis data), while subgroup analysis showed the prognostic values of PLR existed in these studies. Moreover, there are significant heterogeneity existing in OS and DFS analysis. Therefore additional large cohorts of prospective studies are needed to correct for heterogeneity.

In conclusion, peripheral blood PLR was an effective prognostic marker for CRC patients. Elevated PLR was related to worse overall survival and recurrence-free survival, but not for disease-free survival and cancer-specific survival. The prognostic utility of PLR might help to guide use of individual therapies and patient counselling in future.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

PubMed, Web of Science and Embase were searched from inception to September 2016. The search strategy used the keywords as follows: "PLR" or "platelet lymphocyte ratio" or "platelet to lymphocyte ratio" or "platelet-lymphocyte ratio" or "platelet lymphocyte" and "CRC" or "colon neoplasm" or "rectal neoplasm" or "colorectal neoplasm" or "colorectal tumor" or "colorectal cancer" or "colorectal carcinoma". There was no language restriction in our study. References of relevant studies and review articles were searched for potential eligible studies.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

The inclusion criteria in this meta-analysis study were as follows: (1) studies investigated the relationship between PLR and colorectal cancer prognosis or clinical characteristics; (2) the PLR was obtained from a preoperative peripheral blood test; (3) adequate data were provided to measure odds ratio (OR) and hazard ratios (HRs) with 95% confidence intervals (CIs). The exclusion criteria were as follows: (1) unrelated studies, animal experiment, cell experiment, literature reviews, comments, letters, meta analysis, or case reports; (2) studies without sufficient data for analysis; and (3) duplicated publications. When studies with overlapping cases were met, the study with the larger number of patients was included.

Data collection and quality assessment {#s4_3}
--------------------------------------

Relevant datas were professionally extracted by two authors independently, and disagreements were resolved through discussion with a third author. Data collected from each study included first author, publication year, country and ethnicity of the study participants, number of patients, tumor characteristics (stage, location, size, differentiation, lymphovascular invasion, treatment, recurrence), cut off value for high or low PLR, and survival data (OS/DFS/CSS/RFS). If some publications provided survival data by Kaplan-Meier curves indirectly, Engauge Digitizer version 4.1 was applied to extract the data. The quality of included articles were assessed using the Newcastle-Ottawa Scale (NOS) by two authors independently ([Supplementary Table S2](#SD1){ref-type="supplementary-material"} showed the Newcastle-Ottawa quality assessment scale). The total scores of NOS ranged from 0 to 9, with higher scores indicating better quality. A high-quality study was defined as the study with ≥6 points on NOS.

Statistical analysis {#s4_4}
--------------------

According to the cut-off values, PLR was devided into high or low level groups in each study, and the hazard ratio with the 95% confidence interval (high *vs* low level of PLR) were used to evaluate the relationship between PLR and long-term prognosis (OS/DFS/CSS/RFS). Odds ratio and 95%CI were pooled to access the role of PLR on clinical features of colorectal cancer. Statistical heterogeneity was evaluated by Q and I^2^ tests, and if the *p*-value \< 0.1 or I^2^ \> 50%, which suggested the existence of substantial heterogeneity, thus we used a random-effect model to calculate the pooled estimate. Otherwise, the fixed-effect model would be applied instead. The subgroup analyses were applied to explore the heterogeneity sources. Publication bias was evaluated using the Egger\'s weighted linear regression and Begg\'s regression method. A trim and fill method was used when significant publication bias existed. All statistical tests were two-sided, and a *p* value \< 0.05 was considered to be statistically significant. All analyses were conducted by Stata 14.0 (STATA Corporation, College Station, TX, USA).

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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CRC

:   colorectal cancer

PLR

:   platelet-lymphocyte ratio

HR

:   hazard ratio

OR

:   odds ratio

95% CI

:   95% confidence interval

OS

:   overall survival

DFS

:   disease-free survival

RFS

:   recurrence-free survival

CSS

:   Cancer-specific survival

NOS

:   the Newcastle-Ottawa Scale

Ph

:   P-value of heterogeneity
